α2-adrenergic agonist and IGRS (imidazoline I2 binding site) selective ligand.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 291.14. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||3.43 mL||17.17 mL||34.35 mL|
|5 mM||0.69 mL||3.43 mL||6.87 mL|
|10 mM||0.34 mL||1.72 mL||3.43 mL|
|50 mM||0.07 mL||0.34 mL||0.69 mL|
References are publications that support the products' biological activity.
Evans and Anderson (1995) Renal effects of infusion of rilmenidine and guanabenz in conscious dogs: contribution of peripheral and central nervous system α2-adrenoceptors. Br.J.Pharmacol. 116 1557 PMID: 8564219
Holmes et al (1983) Guanabenz. A review of its pharmacodynamic properties and therapeutic efficacy in hypertension. Drugs 26 212 PMID: 6352237
Michel and Insel (1989) Are there multiple imidazoline binding sites? Trends Pharmacol.Sci. 10 342 PMID: 2690423
If you know of a relevant reference for Guanabenz acetate, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Guanabenz acetate, supplier, α2-adrenoceptor, alpha2-adrenoceptor, α2-Adrenergic, alpha2-Adrenergic, a2-adrenoceptor, a2-adrenergic, agonists, I2, selective, ligands, Adrenoceptors, Imidazoline, Adrenergic, Alpha-2, Receptors, I2, Receptors, Adrenergic, Alpha-2, Receptors, Tocris Bioscience
4 Citations for Guanabenz acetate
Citations are publications that use Tocris products. Selected citations for Guanabenz acetate include:
Hamamura et al (2015) Chondroprotective effects of Salubrinal in a mouse model of osteoarthritis. Proc Natl Acad Sci U S A 4 84 PMID: 25977571
Cardin and Schmidt (2004) Noradrenergic inputs mediate state dependence of auditory responses in the avian song system. Bone Joint Res 24 7745 PMID: 15342742
Ye et al (2013) Pharmaceutically controlled designer circuit for the treatment of the metabolic syndrome. J Korean Med Sci 110 141 PMID: 23248313
Wan et al (2014) Distinctive subcellular inhibition of cytokine-induced SRC by salubrinal and fluid flow. PLoS One 9 e105699 PMID: 25157407
Do you know of a great paper that uses Guanabenz acetate from Tocris? If so please let us know.
Reviews for Guanabenz acetate
There are currently no reviews for this product. Be the first to review Guanabenz acetate and earn rewards!
Have you used Guanabenz acetate?
Submit a review and receive an Amazon gift card.
$10US/$10CAN/€7/£6 gift card for a review without an image
$25US/$25CAN/€18/£15 gift card for a review with an image
*Offer only valid in the USA / Canada, UK and EuropeSubmit a Review
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.